Hudson Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.69M | Buy |
52,947
+120
| +0.2% | +$15.8K | 1.62% | 24 |
|
|
2026
Q1 | $7.36M | Buy |
52,827
+791
| +2% | +$111K | 1.9% | 14 |
|
|
2025
Q4 | $6.39M | Sell |
52,036
-873
| -2% | -$106K | 1.6% | 21 |
|
|
2025
Q3 | $5.87M | Sell |
52,909
-644
| -1% | -$73.2K | 1.56% | 26 |
|
|
2025
Q2 | $5.94M | Sell |
53,553
-239
| -0.4% | -$25.4K | 1.68% | 19 |
|
|
2025
Q1 | $6.03M | Sell |
53,792
-2,310
| -4% | -$238K | 1.84% | 14 |
|
|
2024
Q4 | $5.18M | Sell |
56,102
-2,576
| -4% | -$232K | 1.61% | 25 |
|
|
2024
Q3 | $4.92M | Buy |
58,678
+583
| +1% | +$44.5K | 1.57% | 24 |
|
|
2024
Q2 | $3.99M | Buy |
58,095
+9,178
| +19% | +$612K | 1.34% | 37 |
|
|
2024
Q1 | $3.58M | Buy |
48,917
+2,619
| +6% | +$201K | 1.24% | 41 |
|
|
2023
Q4 | $3.75M | Buy |
46,298
+1,401
| +3% | +$109K | 1.36% | 35 |
|
|
2023
Q3 | $3.36M | Buy |
44,897
+2,018
| +5% | +$155K | 1.34% | 33 |
|
|
2023
Q2 | $3.3M | Buy |
42,879
+1,694
| +4% | +$135K | 1.27% | 35 |
|
|
2023
Q1 | $3.42M | Buy |
41,185
+2,007
| +5% | +$166K | 1.36% | 27 |
|
|
2022
Q4 | $3.36M | Buy |
39,178
+800
| +2% | +$63.4K | 1.33% | 23 |
|
|
2022
Q3 | $2.37M | Buy |
38,378
+2,700
| +8% | +$170K | 1.18% | 27 |
|
|
2022
Q2 | $2.21M | Buy |
35,678
+5,065
| +17% | +$314K | 1.05% | 37 |
|
|
2022
Q1 | $1.82M | Buy |
30,613
+2,005
| +7% | +$128K | 0.72% | 45 |
|
|
2021
Q4 | $2.08M | Buy |
28,608
+422
| +1% | +$29.1K | 0.75% | 41 |
|
|
2021
Q3 | $1.97M | Buy |
28,186
+580
| +2% | +$40.7K | 0.79% | 37 |
|
|
2021
Q2 | $1.9M | Buy |
27,606
+439
| +2% | +$29.3K | 0.79% | 43 |
|
|
2021
Q1 | $1.76M | Buy |
27,167
+555
| +2% | +$35.8K | 0.75% | 41 |
|
|
2020
Q4 | $1.55M | Sell |
26,612
-1,227
| -4% | -$74K | 0.69% | 44 |
|
|
2020
Q3 | $1.76M | Buy |
27,839
+1,373
| +5% | +$95.2K | 0.86% | 38 |
|
|
2020
Q2 | $2.04M | Sell |
26,466
-1,901
| -7% | -$146K | 1.08% | 30 |
|
|
2020
Q1 | $2.12M | Sell |
28,367
-331
| -1% | -$22.9K | 1.41% | 20 |
|
|
2019
Q4 | $1.86M | Buy |
28,698
+1,382
| +5% | +$90K | 0.94% | 42 |
|
|
2019
Q3 | $1.73M | Buy |
27,316
+2,524
| +10% | +$165K | 0.96% | 37 |
|
|
2019
Q2 | $1.67M | Buy |
24,792
+3,674
| +17% | +$242K | 0.94% | 37 |
|
|
2019
Q1 | $1.37M | Buy |
21,118
+2,125
| +11% | +$141K | 0.84% | 39 |
|
|
2018
Q4 | $1.19M | Buy |
18,993
+895
| +5% | +$62.6K | 0.87% | 33 |
|
|
2018
Q3 | $1.4M | Buy |
18,098
+337
| +2% | +$25.5K | 1.06% | 27 |
|
|
2018
Q2 | $1.26M | Buy |
17,761
+1,615
| +10% | +$114K | 0.88% | 37 |
|
|
2018
Q1 | $1.22M | Buy |
16,146
+1,939
| +14% | +$154K | 0.9% | 35 |
|
|
2017
Q4 | $1.02M | Buy |
+14,207
| New | +$1.08M | 0.75% | 43 |
|
Other funds holding GILD
LMFP
CIM
ATO
CGH
Hudson Capital Management's GILD Position: Q2 2026 in Review
Hudson Capital Management increased its Gilead Sciences (GILD) stake by 0.23% in Q2 2026, buying an estimated $15.8K and bringing the position to 52,947 shares worth $6.69M. The position accounts for 1.62% of the portfolio, ranked #24.
Hudson Capital Management first reported a position in GILD in Q4 2017 and has held it in 35 quarters since. The position peaked at $7.36M in Q1 2026. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Hudson Capital Management held 52,947 shares of Gilead Sciences worth $6.69M as of Q2 2026.
- Hudson Capital Management bought 120 Gilead Sciences shares in Q2 2026, an estimated $15.8K.
- Gilead Sciences made up 1.62% of Hudson Capital Management's portfolio in Q2 2026, its #24 holding.
- Hudson Capital Management first reported a position in Gilead Sciences in Q4 2017 and has held it in 35 quarters since.
- Hudson Capital Management's Gilead Sciences position peaked at $7.36M in Q1 2026.
- 690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Hudson Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.